INHIBITORS OF ANGIOGENIC FACTORS

A recombinant human Fc fusion protein comprises an Ig-like domain of a first human VEGF receptor, another different Ig-like domain of a second human VEGF receptor, at least yet another Ig-like domain of a third human VEGF receptor, and the Fc portion of the human IgG1. The fusion protein is useful i...

Full description

Saved in:
Bibliographic Details
Main Authors SHEN, WEI YONG, ZHANG, JINZHONG, HU, JOHN ZHENZE, XIA, ZHEN QIN, SEMBA, CHARLES
Format Patent
LanguageEnglish
French
Published 05.05.2022
Subjects
BEER
BIOCHEMISTRY
CHEMISTRY
ENZYMOLOGY
FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIREDCHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERSFROM A RACEMIC MIXTURE
HUMAN NECESSITIES
HYGIENE
MEDICAL OR VETERINARY SCIENCE
METALLURGY
MICROBIOLOGY
MUTATION OR GENETIC ENGINEERING
ORGANIC CHEMISTRY
PEPTIDES
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS
SPIRITS
VINEGAR
WINE
Online AccessGet full text

Cover

More Information
Summary:A recombinant human Fc fusion protein comprises an Ig-like domain of a first human VEGF receptor, another different Ig-like domain of a second human VEGF receptor, at least yet another Ig-like domain of a third human VEGF receptor, and the Fc portion of the human IgG1. The fusion protein is useful in treating or controlling an ocular disease, condition, or disorder that has etiology in aberrant angiogenesis. Selon l'invention, une protéine de fusion Fc humaine de recombinaison comprend un domaine de type Ig d'un premier récepteur du VEGF humain, un autre domaine de type Ig différent d'un second récepteur du VEGF humain, au moins encore un autre domaine de type Ig d'un troisième récepteur du VEGF Humain, et la partie Fc de l'IgG1 humaine. La protéine de fusion est utile dans le traitement ou la lutte contre une maladie, un pathologique état ou un trouble oculaire qui a une étiologie dans une angiogenèse aberrante.
Bibliography:Application Number: CA20213200307